J. B. Chemicals & Pharmaceuticals Limited
JBCHEPHARM
Clasificación en acciones
#3899
J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai,... J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai, India, in 1976, specializes in the development, production, and global distribution of diverse pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients. Among its prominent product offerings are Cilnidipine, Ranitidine, and Metronidazole. Beyond its own brands, the company extends comprehensive contract manufacturing services, covering an extensive spectrum of dosage forms such as tablets, various lozenge types, injectables, gels, creams, ointments, liquid herbal syrups, and capsules. The firm further contributes to diagnostic medicine by supplying contrast agents for advanced imaging techniques like X-ray, MRI, and ultrasound. Its therapeutic expertise encompasses a broad range of medical fields, including gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives, and pharmacovigilance.
Precio por acción
$26.58
Última sincronización: 2026-07-23
Capitalización bursátil
$4.24B
Cambio (1 día)
0.00%
Cambio (1 año)
38.40%
País
IN
Comercio J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM)
Categoría
Healthcare
Ingresos de J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM)
Ingresos en Mar 2026 TTM: $457.75M
Según los últimos informes financieros de J. B. Chemicals & Pharmaceuticals Limited, los ingresos actuales de la empresa (TTM) son $457.75M. En 2024, la empresa obtuvo unos ingresos de $417.85M un aumento con respecto a los ingresos del año 2023, que fueron de $379.23M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de J. B. Chemicals & Pharmaceuticals Limited desde 2005 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $457.75M | -0.08% |
| 2025 | $458.10M | 9.63% |
| 2024 | $417.85M | 10.19% |
| 2023 | $379.23M | 18.75% |
| 2022 | $319.36M | 16.55% |
| 2021 | $274.01M | 18.45% |
| 2020 | $231.33M | -0.24% |
| 2019 | $231.89M | 9.00% |
| 2018 | $212.73M | 5.28% |
| 2017 | $202.07M | 14.60% |
| 2016 | $176.33M | 4.91% |
| 2015 | $168.07M | 7.33% |
| 2014 | $156.59M | 8.27% |
| 2013 | $144.63M | -8.54% |
| 2012 | $158.14M | -16.27% |
| 2011 | $188.85M | 14.47% |
| 2010 | $164.98M | 16.80% |
| 2009 | $141.25M | 0.50% |
| 2008 | $140.54M | 15.92% |
| 2007 | $121.24M | 15.95% |
| 2006 | $104.56M | 27.21% |
| 2005 | $82.19M | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 1,344.40% |
IN
|
